O	0	7	Effects
O	8	10	of
O	11	19	adjuvant
B-intervention	20	30	exemestane
O	31	37	versus
B-control	38	49	anastrozole
O	50	52	on
O	53	57	bone
O	58	65	mineral
O	66	73	density
O	74	77	for
B-eligibility	78	83	women
I-eligibility	84	88	with
I-eligibility	89	94	early
I-eligibility	95	101	breast
I-eligibility	102	108	cancer
I-eligibility	109	110	(
I-eligibility	110	112	MA
I-eligibility	112	113	.
I-eligibility	113	116	27B
I-eligibility	116	117	)
O	117	118	:
O	119	120	a
O	121	130	companion
O	131	139	analysis
O	140	142	of
O	143	144	a
O	145	155	randomised
O	156	166	controlled
O	167	172	trial
O	172	173	.

O	174	183	Treatment
O	184	186	of
O	187	193	breast
O	194	200	cancer
O	201	205	with
O	206	215	aromatase
O	216	226	inhibitors
O	227	229	is
O	230	240	associated
O	241	245	with
O	246	252	damage
O	253	255	to
O	256	261	bones
O	261	262	.

O	263	267	NCIC
O	268	271	CTG
O	272	274	MA
O	274	275	.
O	275	277	27
O	278	281	was
O	282	284	an
O	285	289	open
O	289	290	-
O	290	295	label
O	295	296	,
O	297	302	phase
O	303	304	3
O	304	305	,
O	306	316	randomised
O	317	327	controlled
O	328	333	trial
O	334	336	in
O	337	342	which
O	343	348	women
O	349	353	with
O	354	360	breast
O	361	367	cancer
O	368	372	were
O	373	381	assigned
O	382	384	to
O	385	388	one
O	389	391	of
O	392	395	two
O	396	404	adjuvant
O	405	409	oral
O	410	419	aromatase
O	420	430	inhibitors
O	430	431	-
O	431	441	exemestane
O	442	444	or
O	445	456	anastrozole
O	456	457	.

O	458	460	We
O	461	471	postulated
O	472	476	that
O	477	487	exemestane
O	487	488	-
O	488	489	a
O	490	496	mildly
O	497	507	androgenic
O	508	515	steroid
O	515	516	-
O	516	521	might
O	522	526	have
O	527	528	a
O	529	533	less
O	534	545	detrimental
O	546	552	effect
O	553	555	on
O	556	560	bone
O	561	565	than
O	566	569	non
O	569	570	-
O	570	579	steroidal
O	580	591	anastrozole
O	591	592	.

O	593	595	In
O	596	600	this
O	601	610	companion
O	611	616	study
O	617	619	to
O	620	622	MA
O	622	623	.
O	623	625	27
O	625	626	,
O	627	629	we
O	630	638	compared
O	639	646	changes
O	647	649	in
O	650	654	bone
O	655	662	mineral
O	663	670	density
O	671	672	(
O	672	675	BMD
O	675	676	)
O	677	679	in
O	680	683	the
O	684	690	lumbar
O	691	696	spine
O	697	700	and
O	701	706	total
O	707	710	hip
O	711	718	between
O	719	727	patients
O	728	735	treated
O	736	740	with
O	741	751	exemestane
O	752	755	and
O	756	764	patients
O	765	772	treated
O	773	777	with
O	778	789	anastrozole
O	789	790	.

O	791	793	In
O	794	796	MA
O	796	797	.
O	797	799	27
O	799	800	,
O	801	815	postmenopausal
O	816	821	women
O	822	826	with
O	827	832	early
O	833	838	stage
O	839	846	hormone
O	847	848	(
O	848	857	oestrogen
O	857	858	)
O	859	867	receptor
O	867	868	-
O	868	876	positive
O	877	885	invasive
O	886	892	breast
O	893	899	cancer
O	900	904	were
O	905	913	randomly
O	914	922	assigned
O	923	925	to
O	926	936	exemestane
O	937	939	25
O	940	942	mg
O	943	949	versus
O	950	961	anastrozole
O	962	963	1
O	964	966	mg
O	966	967	,
O	968	973	daily
O	973	974	.

O	975	977	MA
O	977	978	.
O	978	981	27B
O	982	991	recruited
O	992	995	two
O	996	1002	groups
O	1003	1005	of
O	1006	1011	women
O	1012	1016	from
O	1017	1019	MA
O	1019	1020	.
O	1020	1022	27
O	1022	1023	:
O	1024	1029	those
O	1030	1034	with
O	1035	1038	BMD
O	1039	1040	T
O	1040	1041	-
O	1041	1047	scores
O	1048	1050	of
O	1051	1052	-
O	1052	1053	2
O	1053	1054	·
O	1054	1055	0
O	1056	1058	or
O	1059	1063	more
O	1064	1065	(
O	1065	1067	up
O	1068	1070	to
O	1071	1072	2
O	1073	1076	SDs
O	1077	1082	below
O	1083	1086	sex
O	1086	1087	-
O	1087	1094	matched
O	1094	1095	,
O	1096	1101	young
O	1102	1107	adult
O	1108	1112	mean
O	1112	1113	)
O	1114	1117	and
O	1118	1123	those
O	1124	1128	with
O	1129	1131	at
O	1132	1137	least
O	1138	1141	one
O	1142	1143	T
O	1143	1144	-
O	1144	1149	score
O	1150	1151	(
O	1151	1154	hip
O	1155	1157	or
O	1158	1163	spine
O	1163	1164	)
O	1165	1169	less
O	1170	1174	than
O	1175	1176	-
O	1176	1177	2
O	1177	1178	·
O	1178	1179	0
O	1179	1180	.

O	1181	1185	Both
O	1186	1192	groups
O	1193	1201	received
O	1202	1209	vitamin
O	1210	1211	D
O	1212	1215	and
O	1216	1223	calcium
O	1223	1224	;
O	1225	1230	those
O	1231	1235	with
O	1236	1244	baseline
O	1245	1246	T
O	1246	1247	-
O	1247	1253	scores
O	1254	1256	of
O	1257	1261	less
O	1262	1266	than
O	1267	1268	-
O	1268	1269	2
O	1269	1270	·
O	1270	1271	0
O	1272	1276	also
O	1277	1285	received
O	1286	1301	bisphosphonates
O	1301	1302	.

O	1303	1306	The
O	1307	1314	primary
O	1315	1324	endpoints
O	1325	1329	were
B-outcome-Measure	1330	1337	percent
I-outcome-Measure	1338	1344	change
I-outcome-Measure	1345	1347	of
I-outcome-Measure	1348	1351	BMD
I-outcome-Measure	1352	1354	at
I-outcome-Measure	1355	1356	2
I-outcome-Measure	1357	1362	years
I-outcome-Measure	1363	1365	in
I-outcome-Measure	1366	1372	lumbar
I-outcome-Measure	1373	1378	spine
I-outcome-Measure	1379	1382	and
I-outcome-Measure	1383	1388	total
I-outcome-Measure	1389	1392	hip
O	1393	1396	for
O	1397	1401	both
O	1402	1408	groups
O	1408	1409	.

O	1410	1412	We
O	1413	1421	analysed
O	1422	1430	patients
O	1431	1440	according
O	1441	1443	to
O	1444	1449	which
O	1450	1459	aromatase
O	1460	1469	inhibitor
O	1470	1473	and
O	1474	1475	T
O	1475	1476	-
O	1476	1481	score
O	1482	1488	groups
O	1489	1493	they
O	1494	1498	were
O	1499	1508	allocated
O	1509	1511	to
O	1512	1515	but
O	1516	1519	BMD
O	1520	1531	assessments
O	1532	1538	ceased
O	1539	1541	if
O	1542	1550	patients
O	1551	1559	deviated
O	1560	1564	from
O	1565	1573	protocol
O	1573	1574	.

O	1575	1579	This
O	1580	1585	study
O	1586	1588	is
O	1589	1599	registered
O	1600	1604	with
O	1605	1619	ClinicalTrials
O	1619	1620	.
O	1620	1623	gov
O	1623	1624	,
O	1625	1636	NCT00354302
O	1636	1637	.

O	1638	1645	Between
O	1646	1651	April
O	1652	1654	24
O	1654	1655	,
O	1656	1660	2006
O	1660	1661	,
O	1662	1665	and
O	1666	1669	May
O	1670	1672	30
O	1672	1673	,
O	1674	1678	2008
O	1678	1679	,
B-total-participants	1680	1683	300
O	1684	1692	patients
O	1693	1697	with
O	1698	1706	baseline
O	1707	1708	T
O	1708	1709	-
O	1709	1715	scores
O	1716	1718	of
O	1719	1720	-
O	1720	1721	2
O	1721	1722	·
O	1722	1723	0
O	1724	1726	or
O	1727	1731	more
O	1732	1736	were
O	1737	1744	accrued
O	1745	1746	(
B-intervention-participants	1746	1749	147
O	1750	1759	allocated
O	1760	1770	exemestane
O	1770	1771	,
B-control-participants	1772	1775	153
O	1776	1787	anastrozole
O	1787	1788	)
O	1788	1789	;
O	1790	1793	and
B-total-participants	1794	1797	197
O	1798	1806	patients
O	1807	1811	with
O	1812	1820	baseline
O	1821	1822	T
O	1822	1823	-
O	1823	1829	scores
O	1830	1832	of
O	1833	1837	less
O	1838	1842	than
O	1843	1844	-
O	1844	1845	2
O	1845	1846	·
O	1846	1847	0
O	1848	1849	(
B-intervention-participants	1849	1852	101
O	1853	1863	exemestane
O	1863	1864	,
B-control-participants	1865	1867	96
O	1868	1879	anastrozole
O	1879	1880	)
O	1880	1881	.

O	1882	1885	For
O	1886	1894	patients
O	1895	1899	with
O	1900	1901	T
O	1901	1902	-
O	1902	1908	scores
O	1909	1916	greater
O	1917	1921	than
O	1922	1923	-
O	1923	1924	2
O	1924	1925	·
O	1925	1926	0
O	1927	1929	at
O	1930	1938	baseline
O	1938	1939	,
B-outcome	1940	1944	mean
I-outcome	1945	1951	change
I-outcome	1952	1954	of
I-outcome	1955	1959	bone
I-outcome	1960	1967	mineral
I-outcome	1968	1975	density
I-outcome	1976	1978	in
I-outcome	1979	1982	the
I-outcome	1983	1988	spine
I-outcome	1989	1991	at
I-outcome	1992	1993	2
I-outcome	1994	1999	years
O	2000	2003	did
O	2004	2007	not
O	2008	2014	differ
O	2015	2028	significantly
O	2029	2036	between
O	2037	2045	patients
O	2046	2052	taking
O	2053	2063	exemestane
O	2064	2067	and
O	2068	2076	patients
O	2077	2083	taking
O	2084	2095	anastrozole
O	2096	2097	(
B-iv-cont-mean	2097	2098	-
I-iv-cont-mean	2098	2099	0
I-iv-cont-mean	2099	2100	·
I-iv-cont-mean	2100	2102	92
I-iv-cont-mean	2102	2103	%
O	2103	2104	,
O	2105	2107	95
O	2107	2108	%
O	2109	2111	CI
O	2112	2113	-
O	2113	2114	2
O	2114	2115	·
O	2115	2117	35
O	2118	2120	to
O	2121	2122	0
O	2122	2123	·
O	2123	2125	50
O	2126	2128	vs
B-cv-cont-mean	2129	2130	-
I-cv-cont-mean	2130	2131	2
I-cv-cont-mean	2131	2132	·
I-cv-cont-mean	2132	2134	39
I-cv-cont-mean	2134	2135	%
O	2135	2136	,
O	2137	2139	95
O	2139	2140	%
O	2141	2143	CI
O	2144	2145	-
O	2145	2146	3
O	2146	2147	·
O	2147	2149	77
O	2150	2152	to
O	2153	2154	-
O	2154	2155	1
O	2155	2156	·
O	2156	2158	01
O	2158	2159	;
O	2160	2161	p
O	2161	2162	=
O	2162	2163	0
O	2163	2164	·
O	2164	2166	08
O	2166	2167	)
O	2167	2168	.

O	2169	2179	Respective
B-outcome	2180	2184	mean
I-outcome	2185	2189	loss
I-outcome	2190	2192	in
I-outcome	2193	2196	the
I-outcome	2197	2200	hip
O	2201	2204	was
B-iv-cont-mean	2205	2206	-
I-iv-cont-mean	2206	2207	1
I-iv-cont-mean	2207	2208	·
I-iv-cont-mean	2208	2210	93
I-iv-cont-mean	2210	2211	%
O	2212	2213	(
O	2213	2215	95
O	2215	2216	%
O	2217	2219	CI
O	2220	2221	-
O	2221	2222	2
O	2222	2223	·
O	2223	2225	93
O	2226	2228	to
O	2229	2230	-
O	2230	2231	0
O	2231	2232	·
O	2232	2234	93
O	2234	2235	)
O	2236	2242	versus
B-cv-cont-mean	2243	2244	-
I-cv-cont-mean	2244	2245	2
I-cv-cont-mean	2245	2246	·
I-cv-cont-mean	2246	2248	71
I-cv-cont-mean	2248	2249	%
O	2250	2251	(
O	2251	2253	95
O	2253	2254	%
O	2255	2257	CI
O	2258	2259	-
O	2259	2260	4
O	2260	2261	·
O	2261	2263	32
O	2264	2266	to
O	2267	2268	-
O	2268	2269	1
O	2269	2270	·
O	2270	2272	11
O	2272	2273	;
O	2274	2275	p
O	2275	2276	=
O	2276	2277	0
O	2277	2278	·
O	2278	2280	10
O	2280	2281	)
O	2281	2282	.

O	2283	2291	Likewise
O	2292	2295	for
O	2296	2301	those
O	2302	2305	who
O	2306	2313	started
O	2314	2318	with
O	2319	2320	T
O	2320	2321	-
O	2321	2327	scores
O	2328	2330	of
O	2331	2335	less
O	2336	2340	than
O	2341	2342	-
O	2342	2343	2
O	2343	2344	·
O	2344	2345	0
O	2345	2346	,
B-outcome	2347	2351	mean
I-outcome	2352	2358	change
I-outcome	2359	2361	of
I-outcome	2362	2367	spine
I-outcome	2368	2372	bone
I-outcome	2373	2380	mineral
I-outcome	2381	2388	density
I-outcome	2389	2391	at
I-outcome	2392	2393	2
I-outcome	2394	2399	years
O	2400	2403	did
O	2404	2407	not
O	2408	2414	differ
O	2415	2428	significantly
O	2429	2436	between
O	2437	2440	the
O	2441	2451	exemestane
O	2452	2455	and
O	2456	2467	anastrozole
O	2468	2477	treatment
O	2478	2484	groups
O	2485	2486	(
B-iv-cont-mean	2486	2487	2
I-iv-cont-mean	2487	2488	·
I-iv-cont-mean	2488	2490	11
I-iv-cont-mean	2490	2491	%
O	2491	2492	,
O	2493	2495	95
O	2495	2496	%
O	2497	2499	CI
O	2500	2501	-
O	2501	2502	0
O	2502	2503	·
O	2503	2505	84
O	2506	2508	to
O	2509	2510	5
O	2510	2511	·
O	2511	2513	06
O	2514	2516	vs
B-cv-cont-mean	2517	2518	3
I-cv-cont-mean	2518	2519	·
I-cv-cont-mean	2519	2521	72
I-cv-cont-mean	2521	2522	%
O	2522	2523	,
O	2524	2526	95
O	2526	2527	%
O	2528	2530	CI
O	2531	2532	1
O	2532	2533	·
O	2533	2535	54
O	2536	2538	to
O	2539	2540	5
O	2540	2541	·
O	2541	2543	89
O	2543	2544	;
O	2545	2546	p
O	2546	2547	=
O	2547	2548	0
O	2548	2549	·
O	2549	2551	26
O	2551	2552	)
O	2552	2553	,
O	2554	2557	nor
O	2558	2561	did
B-outcome	2562	2565	hip
I-outcome	2566	2570	bone
I-outcome	2571	2578	mineral
I-outcome	2579	2586	density
O	2587	2588	(
B-iv-cont-mean	2588	2589	2
I-iv-cont-mean	2589	2590	·
I-iv-cont-mean	2590	2592	09
I-iv-cont-mean	2592	2593	%
O	2593	2594	,
O	2595	2597	95
O	2597	2598	%
O	2599	2601	CI
O	2602	2603	-
O	2603	2604	1
O	2604	2605	·
O	2605	2607	45
O	2608	2610	to
O	2611	2612	5
O	2612	2613	·
O	2613	2615	63
O	2616	2618	vs
B-cv-cont-mean	2619	2620	0
I-cv-cont-mean	2620	2621	·
I-cv-cont-mean	2621	2622	0
I-cv-cont-mean	2622	2623	%
O	2623	2624	,
O	2625	2627	95
O	2627	2628	%
O	2629	2631	CI
O	2632	2633	-
O	2633	2634	3
O	2634	2635	·
O	2635	2637	67
O	2638	2640	to
O	2641	2642	3
O	2642	2643	·
O	2643	2645	66
O	2645	2646	;
O	2647	2648	p
O	2648	2649	=
O	2649	2650	0
O	2650	2651	·
O	2651	2653	28
O	2653	2654	)
O	2654	2655	.

O	2656	2664	Patients
O	2665	2669	with
O	2670	2678	baseline
O	2679	2680	T
O	2680	2681	-
O	2681	2686	score
O	2687	2689	of
O	2690	2691	-
O	2691	2692	2
O	2692	2693	·
O	2693	2694	0
O	2695	2697	or
O	2698	2702	more
O	2703	2709	taking
O	2710	2720	exemestane
O	2721	2724	had
B-iv-bin-abs	2725	2728	two
B-outcome	2729	2738	fragility
I-outcome	2739	2748	fractures
O	2749	2752	and
B-iv-bin-abs	2753	2756	two
B-outcome	2757	2762	other
I-outcome	2763	2772	fractures
O	2772	2773	,
O	2774	2779	those
O	2780	2786	taking
O	2787	2798	anastrozole
O	2799	2802	had
B-cv-bin-abs	2803	2808	three
B-outcome	2809	2818	fragility
I-outcome	2819	2828	fractures
O	2829	2832	and
B-cv-bin-abs	2833	2837	five
B-outcome	2838	2843	other
I-outcome	2844	2853	fractures
O	2853	2854	.

O	2855	2858	For
O	2859	2867	patients
O	2868	2871	who
O	2872	2875	had
O	2876	2884	baseline
O	2885	2886	T
O	2886	2887	-
O	2887	2893	scores
O	2894	2896	of
O	2897	2901	less
O	2902	2906	than
O	2907	2908	-
O	2908	2909	2
O	2909	2910	·
O	2910	2911	0
O	2912	2918	taking
O	2919	2929	exemestane
O	2929	2930	,
B-iv-bin-abs	2931	2934	one
O	2935	2938	had
O	2939	2940	a
B-outcome	2941	2950	fragility
I-outcome	2951	2959	fracture
O	2960	2963	and
B-iv-bin-abs	2964	2968	four
O	2969	2972	had
B-outcome	2973	2978	other
I-outcome	2979	2988	fractures
O	2988	2989	,
O	2990	2997	whereas
O	2998	3003	those
O	3004	3010	taking
O	3011	3022	anastrozole
O	3023	3026	had
B-cv-bin-abs	3027	3031	five
B-outcome	3032	3041	fragility
I-outcome	3042	3051	fractures
O	3052	3055	and
B-cv-bin-abs	3056	3059	one
B-outcome	3060	3065	other
I-outcome	3066	3074	fracture
O	3074	3075	.

O	3076	3079	Our
O	3080	3087	results
O	3088	3099	demonstrate
O	3100	3104	that
O	3105	3113	adjuvant
O	3114	3123	treatment
O	3124	3128	with
O	3129	3138	aromatase
O	3139	3149	inhibitors
O	3150	3153	can
O	3154	3156	be
O	3157	3167	considered
O	3168	3171	for
O	3172	3178	breast
O	3179	3185	cancer
O	3186	3194	patients
O	3195	3198	who
O	3199	3203	have
O	3204	3205	T
O	3205	3206	-
O	3206	3212	scores
O	3213	3217	less
O	3218	3222	than
O	3223	3224	-
O	3224	3225	2
O	3225	3226	·
O	3226	3227	0
O	3227	3228	.

O	3229	3237	Canadian
O	3238	3244	Cancer
O	3245	3252	Society
O	3253	3261	Research
O	3262	3271	Institute
O	3271	3272	,
O	3273	3279	Pfizer
O	3279	3280	,
O	3281	3289	Canadian
O	3290	3300	Institutes
O	3301	3303	of
O	3304	3310	Health
O	3311	3319	Research
O	3319	3320	.
